Samir Taneja, M.D.
- Medical Education: Northwestern University Medical School
- Internship: UCLA School of Medicine, 1992
- Residency Training: (Urology) UCLA School of Medicine, 1996
- Board Certification: American Board of Urology
About Dr. Taneja
Samir S. Taneja, M.D. is the James M. Neissa and Janet Riha Neissa Associate Professor of Urologic Oncology, Director of the Division of Urologic Oncology in the Department of Urology at the NYU Langone Medical Center, Program Leader of the Genitourinary Oncology Program of the NYU Cancer Institute, and, currently, Chief of the Urology Section at the Veterans Administration New York Harbor Healthcare System Manhattan Campus (Manhattan VA Medical Center). Dr. Taneja received his undergraduate and medical education at Northwestern University Medical School. He completed his surgical and urologic training at the University of California at Los Angeles and joined the NYU faculty in 1996.
Dr Taneja is nationally renowned as a leader in the treatment and research of urologic cancers. He has served as Oncology Task Force Member and Chair for the American Board of Urology Exam Committee, Program Chair and Executive Committee Member for the Society of Urologic Oncology, and, most recently, Secretary General of the Urologic Research Society. He has authored over 110 articles, 20 book chapters, and 5 textbooks on urologic cancer and urologic surgery. He is the editor of the 3rd and 4th editions of Complications of Urologic Surgery: Prevention and Diagnosis, one of the most widely read textbooks in American urology. As such he is widely called upon as an expert consultant in complex and difficult urologic surgical cases. Dr Taneja has lectured throughout the world on urologic cancers and urologic surgery, having served as a visiting professor/lecturer in four continents. Throughout his career Dr Taneja has been interviewed on a number of television and radio shows ranging from ABC World News, to Fox News, to Entertainment Tonight. He is currently a weekly host of The Men’s Health Show on Sirius/XM satellite radio.
Dr Taneja is among the most experienced urologic oncologists in the northeast, having performed over 2000 surgical procedures for the treatment of prostate, kidney, bladder, and testis cancers. His surgical outcomes stand among the best in the region. Dr Taneja has extensive experience the surgical and non-surgical treatment of prostate cancer, surgical treatment of early stage kidney tumors by partial nephrectomy (partial removal of the kidney), and radical surgery for locally advanced kidney and bladder cancers. Having extensive experience in open, laparoscopic, and robotic surgical techniques, Dr Taneja’s surgical approach is based upon individual evaluation of the patient’s tumors and selection of the proper technique for optimal cancer control. While minimally-invasive approaches are appropriate for the vast majority of patients, in those for whom they are not, Dr Taneja has great comfort level in offering conventional surgical approaches to maximize the likelihood of successful treatment and minimize the risk of complication. In addition to his surgical practice, Dr Taneja oversees a multidisciplinary oncology group within the NYU Cancer Institute, focused on development of novel approaches to therapy and prevention. He has been listed consistently for the past several years among New York Magazine's ‘Best Doctors’, Castle Connolly's America's Top Doctors for Cancer, Castle Connolly’s America's Top Doctors, Consumer Research Council’s America’s Top Physicians, Best Doctors, and the New York Times Magazine’s Super Doctors.
Dr Taneja’s expertise in prostate cancer includes robotic and open nerve-sparing prostatectomy, interstitial seed implantation, and whole gland prostate ablation by cryotherapy or high-intensity focused ultrasound. He has recently initiated two clinical protocols in focal therapy for prostate cancer and has a large program in active surveillance for men with low risk disease. Having performed several hundred radical prostatectomy procedures since 1996, Dr Taneja converted his practice to robotic radical prostatectomy procedures in 2008 with the intent of improving short-term outcomes in the care of his patients. Dr Taneja’s experience in open radical prostatectomy has given him a unique perspective in performing robotic procedures and attempting to further refine the technique for improved outcomes. Dr Taneja’s approach to prostate cancer for the past many years has been one of individualized prostate cancer care utilizing his expertise in multiple techniques of therapy to offer the patient maximal outcome with the desired therapeutic approach. This is consistent with the mission of the newly designated Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center. To this end, Dr Taneja’s most recent interest is in the development of strategies to treat only the cancerous portion of the prostate in order to minimize the damage to sexual and urinary function in men with low risk disease. Dr Taneja’s expertise in prostate cancer is nationally recognized having written 3 textbook chapters on the technique of radical prostatectomy, lectured extensively on the management of the disease, and, most recently, being invited to give the “take home’ message in localized prostate cancer at the 2009 national meeting of the American Urological Association.
In the treatment of kidney cancer, Dr Taneja’s primary interest for the past 13 years has been in performing partial nephrectomy procedures by open or minimally invasive technique. Having trained at UCLA, one of the premier kidney cancer centers in the world, Dr Taneja came to NYU with specialized knowledge of the disease and its surgical management. As in the case of prostate surgery, Dr Taneja has vast experience in the technique of open partial nephrectomy, having performed several hundred procedures with reported outcomes among the best in the country (?REF). 8 years ago, Dr Taneja integrated laparoscopy into his surgical approach for renal tumors, and now approximately 85-90% of his partial nephrectomy procedures are performed by minimally invasive technique. He has performed over 250 laparoscopic partial nephrectomy procedures with clinical outcomes comparable to those he has reported for open partial nephrectomy. Dr Taneja’s approach to kidney tumors is similar to his approach to prostate cancer. Each patient and his/her tumor is evaluated individually to decide upon the optimal approach to balance cancer cure, risk of complication, and preservation of long-term kidney function. While the majority of kidney tumors can be removed by minimally invasive technique, Dr Taneja does not believe one technique is right for every patient. His expertise in open, laparoscopic, and robotic techniques allows him to maximize patient outcomes individually.
In addition to his experience in partial nephrectomy, Dr Taneja has published and lectured extensively in the area of surgical management of advanced kidney cancer. He has experience in techniques of tumor thrombus extraction, locoregional organ resection, and retrieval of tumor from the heart by cardiac bypass. In these cases, Dr Taneja utilizes a team of experienced surgeons from the NYU Langone Medical Center. Dr Taneja is nationally recognized for his expertise in kidney cancer having served on the faculty of the International Kidney Cancer Symposium, the American Urological Association Renal Cancer Course, editing a book on kidney cancer, contributing to 4 books on kidney cancer, and having been invited to author 4 book chapters on the technique of partial nephrectomy including the chapter in the premier urologic surgical text, Glenn’s Urological Surgery, 7th ed.
In addition to his surgical and clinical expertise, Dr Taneja has been widely recognized for his research accomplishments. When he joined the NYU faculty in 1996, Dr Taneja was named the American Urological Association/ American Foundation for Urological Disease Prostate Health Council Scholar for the study of how testosterone regulates prostate cancer growth. His basic research has been funded by research grants from the National Institutes of Health, the Department of Defense, the Prostate Cancer Foundation, the Chemotherapy Foundation, and a number of private foundations. He has completed 24 research grants as primary or co-investigator and his work was key in initiating the Androgen Receptor Working Group of the Urologic Diseases Center of Excellence at NYU Langone. He has served on multiple research review committees for the National Institutes of Health, the Department of Defense, the American Foundation for Urologic Disease, and the New York Academy of Health, including previous appointment to the National Institutes of Health Special Emphasis Panel for review of Specialized Programs of Research Excellence (SPORE) in prostate cancer.
Dr Taneja has conducted 14 clinical trials at NYU, and has served as national primary investigator for 3 multicenter clinical trials. Currently, he is primary investigator of a 1590 patient study of prostate cancer prevention among men with high grade prostatic intraepithelial neoplasia (sponsor GTX Inc, Memphis) and a 30 patient study of targeted photodynamic therapy for the focal treatment of prostate cancer (sponsor Steba Biotech, Paris, France). The majority of Dr Taneja’s clinical trials have focused in prostate cancer diagnosis, prevention, and treatment.
Dr Taneja’s clinical research also focuses in prostate cancer. He has written extensively on strategies for optimizing the diagnosis of prostate cancer, biopsy techniques, prevention, and management of high risk and recurrent prostate cancer. His most recent interest is in pursuing better methods for mapping and staging prostate cancer. He has recently completed a four center evaluation of a novel computerized biopsy system called Targetscan TM. Having recently received a large patient-directed research gift, Dr Taneja has formed a prostate cancer diagnostic working group with the mission of developing prostate biopsy and imaging techniques which will improve prostate cancer diagnosis, monitoring on active surveillance, and planning for focal therapies for prostate cancer.